Insights Into Multiple Myeloma (MM)
Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents
Faculty Chair
Melissa Alsina, MD
Moffitt Cancer Center, Tampa, FL, USA
Faculty Chair
Hans Lee, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Co-Chair
Sarah A. Holstein, MD, PhD
University of Nebraska Medical Center, Omaha, NE, USA
Faculty Co-Chair
David Dingli, MD
Mayo Clinic, Rochester, MN, USA
Faculty Chair
Saad Usmani, MD, FACP, FASCO
Sloan Kettering Cancer Center, New York, NY, USA
Faculty Chair
Binod Dhakal, MD
Medical College of Wisconsin, Milwaukee, WI, USA
Faculty Chair
Murali Janakiram, MD
City of Hope, Duarte, CA, USA
More Information
- Tampa, FL
- Florida
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- San Diego, CA
- California
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of MM
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region